Current stock page

Stock Analysis

Tango Therapeutics, Inc. (TNGX) Stock Analysis

Tango Therapeutics, Inc. (TNGX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TNGX Stock Analysis Summary

Tango Therapeutics, Inc. (TNGX) currently has an AIQ Score of 61/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TNGX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$25.50
AIQ Score61/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$4.44B
P/E Ratio (TTM)-18.48
Forward P/E—
EPS (Q3 FY2026)-$0.39
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.61
Volume2.71M
52-week range$7.49-$34.39
RSI 1457.02
50-Day SMA$23.53
200-Day SMA$22.90
Analyst Price Target$56.00
Next EarningsMar 4, 2027
As of Nov 13, 2026 · Market close

TNGXTango Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$25.50+$0.65 (+2.62%)

Latest quote

  • Momentum
    60
  • Value
    —
  • Quality
    73
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TNGX Stock Analysis Summary

Tango Therapeutics, Inc. (TNGX) currently has an AIQ Score of 61/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk resilience is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, TNGX has AIQ Score of 61/100 with Quality base of 73/100 and fading Risk resilience at 38/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (73/100) leads while Risk resilience (38/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 2.62% stock move · TNGX classified in Biotechnology.

Current Evidence

NeutralTNGX is in a neutral AIQ regime; Quality is the strongest visible factor at 73/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TNGX Bullish or Bearish Right Now?

TNGX currently has a neutral overall setup. Quality is the strongest factor at 73/100, while Risk Resilience is weakest at 38/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 73/100.
  • - Price is +8.39% above its 50-day SMA.
  • - Analyst target implies +119.61% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (33 vs 8).
Bear Case
  • - Risk Resilience is weak at 38/100.

Current Consensus

TNGX's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 5 neutral, and 8 sell votes. TNGX's 14-day RSI is 57.02, which places the stock in a constructive momentum range. TNGX's beta is 1.61, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in TNGX?

The largest recent change in TNGX is AIQ Score moving up by 10.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+10.0
Momentum
+10.0
Quality
+9.0
Risk
+1.0

What Would Change the TNGX Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TNGX Decision Framework

Public evidence layers, setup checks, and risk context for Tango Therapeutics, Inc..

Tango Therapeutics, Inc. (TNGX) Stock Analysis

Tango Therapeutics, Inc. has an AIQ Score of 61/100 in a Neutral regime. Quality is strongest at 73/100. Beta is 1.61, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTNGX is in a Neutral AIQ regime with score 61/100.
Signal ConflictThe primary conflict is that quality leads at 73/100 while risk lags at 38/100.
Factor EvidenceMomentum 60/100 · Quality 73/100 · Risk 38/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 73/100.

TimingWait

Momentum is 60/100 and RSI (14) is 57.0.

Regime fitWait

TNGX is in a Neutral regime at 61/100.

Risk controlFail

Risk factor is 38/100 with beta 1.61 and annual volatility 101.07%.

ConflictWait

Current conflict: quality leads at 73/100 while risk lags at 38/100.

AIQ Score
61/100
Price
$25.50
Beta
1.61
RSI (14)
57

TNGX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TNGX Fundamentals

TNGX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$68.39M
Free cash flow
-$37.22M
View full TNGX fundamental analysis

TNGX Technical Analysis

TNGX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
57.02
Price vs SMA-50
+8.39%
View full TNGX technical analysis

TNGX Stock Catalysts

Track TNGX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 4, 2027
Analyst target
$56.00
News items
5
View TNGX earnings and stock catalysts

TNGX Dividend Analysis

TNGX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TNGX dividend history and analysis

TNGX Financial Data

TNGX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.39
Periods
8
View TNGX financials

TNGX Risk Analysis

TNGX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.61
Risk score
38/100
1Y volatility
101.07%
View TNGX risk analysis

TNGX Stock News

TNGX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read TNGX stock news

TNGX vs Biotechnology Peers

Current peer cohort: TNGX · TRVI · TSHA · TVTX · TWST. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TNGX
Current stock
61/100—60/10038/1001.61101.07%Current
TRVI
Trevi Therapeutics, Inc.
63/100—52/10051/1000.5259.27%TNGX vs TRVI
TSHA
Taysha Gene Therapies, Inc.
35/100—32/10037/1000.3270.69%TNGX vs TSHA
TVTX
Travere Therapeutics, Inc.
64/10069/10067/10055/1000.8762.28%TNGX vs TVTX
TWST
Twist Bioscience Corporation
64/10058/10084/10032/1001.9484.18%TNGX vs TWST
Pairwise Compare links: TRVI · TSHA · TVTX · TWSTTNGX vs TRVITNGX vs TSHATNGX vs TVTXTNGX vs TWSTCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TNGX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TNGX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-18.48
As of Nov 13, 2026
Revenue growth
-100.00%
Gross margin
0.00%
Current debt / equity
0.03
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$68.39M
Quarter free cash flow
-$37.22M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
57.02
MACD
0.24

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
38/100
Beta
1.61
Annual volatility
101.07%
Max drawdown
-36.57%

TNGX Stock FAQ

What is TNGX stock price today?

Tango Therapeutics, Inc.'s current stock price is $25.50. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TNGX bullish or bearish right now?

TNGX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TNGX's market cap?

TNGX's market cap is $4.44B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TNGX's current P/E ratio?

TNGX's current P/E ratio is -18.48 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TNGX's RSI?

TNGX's 14-day RSI is 57.02 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TNGX above its 50-day and 200-day moving averages?

TNGX is 8.39% from its 50-day SMA and 11.37% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TNGX's next earnings date?

TNGX's next earnings date is currently listed as Mar 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TNGX pay a dividend?

TNGX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.